Genzyme, the beleaguered biotechnology company, said on Wednesday that it expected to be fined at least $175 million by the Food and Drug Administration because of manufacturing problems that have caused severe shortages of two of its best-selling drugs.
via nytimes.com
No comments:
Post a Comment